AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Union Pacific Corp. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Rhythm Pharmaceuticals (RYTM) â€� insider Form 4 filing

Chief Scientific Officer Alastair Garfield settled 4,445 restricted stock units on 1-Jul-2025, receiving an equal number of common shares. On 2-Jul-2025 he sold 1,319 of those shares in two trades at prices of $64.81 and $64.60 under a pre-arranged Rule 10b5-1 plan adopted 25-Jun-2024, with the stated purpose of covering withholding taxes. After the transactions he retains 3,126 directly held shares and 13,333 unvested RSUs that vest 25 % annually through 1-Jul-2028, subject to continued employment. No other equity instruments were created or disposed of. Given the modest size of the sale relative to Rhythm’s share count and its tax-related rationale, the event is viewed as routine compensation management with limited signaling value for investors.

Rhythm Pharmaceuticals (RYTM) � comunicazione interna Modulo 4

Il Chief Scientific Officer Alastair Garfield ha convertito 4.445 unità azionarie vincolate in azioni ordinarie il 1° luglio 2025, ricevendo un numero equivalente di azioni comuni. Il 2 luglio 2025 ha venduto 1.319 di queste azioni in due operazioni a prezzi di 64,81 $ e 64,60 $, nell’ambito di un piano predefinito conforme alla Regola 10b5-1 adottato il 25 giugno 2024, con l’obiettivo dichiarato di coprire le imposte da trattenere. Dopo tali operazioni detiene direttamente 3.126 azioni e 13.333 unità azionarie vincolate non ancora maturate, che maturano al 25% annuo fino al 1° luglio 2028, subordinatamente alla permanenza in azienda. Non sono stati creati o ceduti altri strumenti azionari. Considerando la modesta entità della vendita rispetto al numero totale di azioni di Rhythm e la motivazione fiscale, l’evento è considerato una gestione ordinaria della compensazione con un valore informativo limitato per gli investitori.

Rhythm Pharmaceuticals (RYTM) � presentación interna Formulario 4

El Director Científico Alastair Garfield liquidó 4.445 unidades restringidas de acciones el 1 de julio de 2025, recibiendo un número igual de acciones ordinarias. El 2 de julio de 2025 vendió 1.319 de esas acciones en dos operaciones a precios de 64,81 $ y 64,60 $, bajo un plan preestablecido conforme a la Regla 10b5-1 adoptado el 25 de junio de 2024, con el propósito declarado de cubrir impuestos retenidos. Tras las transacciones, mantiene 3.126 acciones en propiedad directa y 13.333 unidades restringidas no devengadas que se liberan un 25 % anual hasta el 1 de julio de 2028, sujeto a la continuidad laboral. No se crearon ni dispusieron otros instrumentos de capital. Dado el tamaño moderado de la venta en relación con el número de acciones de Rhythm y su justificación fiscal, el evento se considera una gestión rutinaria de compensación con un valor informativo limitado para los inversores.

Rhythm Pharmaceuticals (RYTM) � 내부� Form 4 제출

최고 과학 ì±…ìž„ìž� 알ë¼ìŠ¤í…Œì–� 가필드ëŠ� 2025ë…� 7ì›� 1ì¼ì— 4,445ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„ë¥� 정산하여 ë™ì¼ ìˆ˜ì˜ ë³´í†µì£¼ë¥¼ 받았습니ë‹�. 2025ë…� 7ì›� 2ì�, 그는 2024ë…� 6ì›� 25ì� 채íƒë� 사전 계íšë� Rule 10b5-1 계íšì—� ë”°ë¼ $64.81ê³� $64.60ì� 가격으ë¡� ë‘� 차례 거래ì—서 해당 ì£¼ì‹ ì¤� 1,319주를 매ë„했으ë©�, ì´ëŠ” ì›ì²œì§•수ì„� ë‚©ë¶€ 목ì ì´ì—ˆìŠµë‹ˆë‹�. 거래 í›� 그는 ì§ì ‘ 보유í•� 3,126주와 2028ë…� 7ì›� 1ì¼ê¹Œì§€ 매년 25%ì”� 권리가 부여ë˜ëŠ� 13,333ì£¼ì˜ ë¯¸í™•ì � RSUë¥� 보유하고 있으ë©�, ì´ëŠ” ê³„ì† ê³ ìš© ì¡°ê±´ì—� 따릅니다. 다른 ì£¼ì‹ ê´€ë � 금융ìƒí’ˆì€ ìƒì„±ë˜ê±°ë‚� 처분ë˜ì§€ 않았습니ë‹�. ë§¤ë„ ê·œëª¨ê°€ Rhythmì� ì£¼ì‹ ìˆ˜ì— ë¹„í•´ ì ê³  세금 ê´€ë � 목ì ìž„ì„ ê³ ë ¤í•� ë•�, ì� ì‚¬ê±´ì€ íˆ¬ìžìžì—ê²� í� 신호ë¥� 주지 않는 ì¼ìƒì ì¸ ë³´ìƒ ê´€ë¦¬ë¡œ 간주ë©ë‹ˆë‹�.

Rhythm Pharmaceuticals (RYTM) � déclaration d’initié Formulaire 4

Le directeur scientifique Alastair Garfield a réglé 4 445 unités d’actions restreintes le 1er juillet 2025, recevant un nombre équivalent d’actions ordinaires. Le 2 juillet 2025, il a vendu 1 319 de ces actions en deux transactions aux prix de 64,81 $ et 64,60 $, dans le cadre d’un plan préétabli conforme à la règle 10b5-1 adopté le 25 juin 2024, dans le but déclaré de couvrir les impôts à la source. Après ces opérations, il détient 3 126 actions directement et 13 333 unités d’actions restreintes non acquises, qui acquièrent 25 % par an jusqu’au 1er juillet 2028, sous réserve de son maintien dans l’entreprise. Aucun autre instrument de capitaux propres n’a été créé ou cédé. Étant donné la taille modeste de la vente par rapport au nombre d’actions de Rhythm et sa justification fiscale, cet événement est considéré comme une gestion courante de la rémunération avec une valeur informative limitée pour les investisseurs.

Rhythm Pharmaceuticals (RYTM) � Insider Form 4 Meldung

Der Chief Scientific Officer Alastair Garfield hat am 1. Juli 2025 4.445 Restricted Stock Units eingelöst und dafür die gleiche Anzahl an Stammaktien erhalten. Am 2. Juli 2025 verkaufte er 1.319 dieser Aktien in zwei Transaktionen zu Preisen von 64,81 $ und 64,60 $ im Rahmen eines vorab vereinbarten Rule 10b5-1 Plans, der am 25. Juni 2024 eingeführt wurde, mit dem erklärten Zweck, Quellensteuern zu begleichen. Nach den Transaktionen hält er 3.126 direkt gehaltene Aktien und 13.333 nicht ausgeübte RSUs, die jährlich zu 25 % bis zum 1. Juli 2028 vesten, vorbehaltlich einer fortlaufenden Anstellung. Es wurden keine weiteren Aktieninstrumente geschaffen oder veräußert. Angesichts der vergleichsweise geringen Verkaufsmenge im Verhältnis zur Gesamtzahl der Rhythm-Aktien und des steuerlichen Hintergrunds wird das Ereignis als routinemäßiges Vergütungsmanagement mit begrenzter Signalwirkung für Investoren eingestuft.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting; minor tax-related sale; neutral signal for RYTM shareholders.

The CSO converted 4,445 RSUs and sold 1,319 shares (~$85k gross proceeds) strictly to satisfy tax obligations. His remaining equity exposureâ€�3,126 shares plus 13,333 unvested RSUs—maintains alignment with shareholders. Volume is immaterial against Rhythm’s ~60 million shares outstanding and does not suggest strategic de-risking. I classify the filing as informationally neutral and not price-moving.

TL;DR: Pre-planned 10b5-1 sale limits governance concerns; impact minimal.

The transaction followed a disclosed 10b5-1 plan, reinforcing compliance with updated SEC affirmative-defense rules. No red flags arise: sale size is small, purpose is tax coverage, and long-term incentives remain intact. The event demonstrates proper governance practices and transparent insider trading controls, but it carries negligible financial impact.

Rhythm Pharmaceuticals (RYTM) � comunicazione interna Modulo 4

Il Chief Scientific Officer Alastair Garfield ha convertito 4.445 unità azionarie vincolate in azioni ordinarie il 1° luglio 2025, ricevendo un numero equivalente di azioni comuni. Il 2 luglio 2025 ha venduto 1.319 di queste azioni in due operazioni a prezzi di 64,81 $ e 64,60 $, nell’ambito di un piano predefinito conforme alla Regola 10b5-1 adottato il 25 giugno 2024, con l’obiettivo dichiarato di coprire le imposte da trattenere. Dopo tali operazioni detiene direttamente 3.126 azioni e 13.333 unità azionarie vincolate non ancora maturate, che maturano al 25% annuo fino al 1° luglio 2028, subordinatamente alla permanenza in azienda. Non sono stati creati o ceduti altri strumenti azionari. Considerando la modesta entità della vendita rispetto al numero totale di azioni di Rhythm e la motivazione fiscale, l’evento è considerato una gestione ordinaria della compensazione con un valore informativo limitato per gli investitori.

Rhythm Pharmaceuticals (RYTM) � presentación interna Formulario 4

El Director Científico Alastair Garfield liquidó 4.445 unidades restringidas de acciones el 1 de julio de 2025, recibiendo un número igual de acciones ordinarias. El 2 de julio de 2025 vendió 1.319 de esas acciones en dos operaciones a precios de 64,81 $ y 64,60 $, bajo un plan preestablecido conforme a la Regla 10b5-1 adoptado el 25 de junio de 2024, con el propósito declarado de cubrir impuestos retenidos. Tras las transacciones, mantiene 3.126 acciones en propiedad directa y 13.333 unidades restringidas no devengadas que se liberan un 25 % anual hasta el 1 de julio de 2028, sujeto a la continuidad laboral. No se crearon ni dispusieron otros instrumentos de capital. Dado el tamaño moderado de la venta en relación con el número de acciones de Rhythm y su justificación fiscal, el evento se considera una gestión rutinaria de compensación con un valor informativo limitado para los inversores.

Rhythm Pharmaceuticals (RYTM) � 내부� Form 4 제출

최고 과학 ì±…ìž„ìž� 알ë¼ìŠ¤í…Œì–� 가필드ëŠ� 2025ë…� 7ì›� 1ì¼ì— 4,445ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„ë¥� 정산하여 ë™ì¼ ìˆ˜ì˜ ë³´í†µì£¼ë¥¼ 받았습니ë‹�. 2025ë…� 7ì›� 2ì�, 그는 2024ë…� 6ì›� 25ì� 채íƒë� 사전 계íšë� Rule 10b5-1 계íšì—� ë”°ë¼ $64.81ê³� $64.60ì� 가격으ë¡� ë‘� 차례 거래ì—서 해당 ì£¼ì‹ ì¤� 1,319주를 매ë„했으ë©�, ì´ëŠ” ì›ì²œì§•수ì„� ë‚©ë¶€ 목ì ì´ì—ˆìŠµë‹ˆë‹�. 거래 í›� 그는 ì§ì ‘ 보유í•� 3,126주와 2028ë…� 7ì›� 1ì¼ê¹Œì§€ 매년 25%ì”� 권리가 부여ë˜ëŠ� 13,333ì£¼ì˜ ë¯¸í™•ì � RSUë¥� 보유하고 있으ë©�, ì´ëŠ” ê³„ì† ê³ ìš© ì¡°ê±´ì—� 따릅니다. 다른 ì£¼ì‹ ê´€ë � 금융ìƒí’ˆì€ ìƒì„±ë˜ê±°ë‚� 처분ë˜ì§€ 않았습니ë‹�. ë§¤ë„ ê·œëª¨ê°€ Rhythmì� ì£¼ì‹ ìˆ˜ì— ë¹„í•´ ì ê³  세금 ê´€ë � 목ì ìž„ì„ ê³ ë ¤í•� ë•�, ì� ì‚¬ê±´ì€ íˆ¬ìžìžì—ê²� í� 신호ë¥� 주지 않는 ì¼ìƒì ì¸ ë³´ìƒ ê´€ë¦¬ë¡œ 간주ë©ë‹ˆë‹�.

Rhythm Pharmaceuticals (RYTM) � déclaration d’initié Formulaire 4

Le directeur scientifique Alastair Garfield a réglé 4 445 unités d’actions restreintes le 1er juillet 2025, recevant un nombre équivalent d’actions ordinaires. Le 2 juillet 2025, il a vendu 1 319 de ces actions en deux transactions aux prix de 64,81 $ et 64,60 $, dans le cadre d’un plan préétabli conforme à la règle 10b5-1 adopté le 25 juin 2024, dans le but déclaré de couvrir les impôts à la source. Après ces opérations, il détient 3 126 actions directement et 13 333 unités d’actions restreintes non acquises, qui acquièrent 25 % par an jusqu’au 1er juillet 2028, sous réserve de son maintien dans l’entreprise. Aucun autre instrument de capitaux propres n’a été créé ou cédé. Étant donné la taille modeste de la vente par rapport au nombre d’actions de Rhythm et sa justification fiscale, cet événement est considéré comme une gestion courante de la rémunération avec une valeur informative limitée pour les investisseurs.

Rhythm Pharmaceuticals (RYTM) � Insider Form 4 Meldung

Der Chief Scientific Officer Alastair Garfield hat am 1. Juli 2025 4.445 Restricted Stock Units eingelöst und dafür die gleiche Anzahl an Stammaktien erhalten. Am 2. Juli 2025 verkaufte er 1.319 dieser Aktien in zwei Transaktionen zu Preisen von 64,81 $ und 64,60 $ im Rahmen eines vorab vereinbarten Rule 10b5-1 Plans, der am 25. Juni 2024 eingeführt wurde, mit dem erklärten Zweck, Quellensteuern zu begleichen. Nach den Transaktionen hält er 3.126 direkt gehaltene Aktien und 13.333 nicht ausgeübte RSUs, die jährlich zu 25 % bis zum 1. Juli 2028 vesten, vorbehaltlich einer fortlaufenden Anstellung. Es wurden keine weiteren Aktieninstrumente geschaffen oder veräußert. Angesichts der vergleichsweise geringen Verkaufsmenge im Verhältnis zur Gesamtzahl der Rhythm-Aktien und des steuerlichen Hintergrunds wird das Ereignis als routinemäßiges Vergütungsmanagement mit begrenzter Signalwirkung für Investoren eingestuft.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DILLON DAVID B

(Last) (First) (Middle)
1400 DOUGLAS STREET

(Street)
OMAHA NE 68179

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
UNION PACIFIC CORP [ UNP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock(1) $0.0 07/01/2025 A 257 (2) (2) Common Stock 257 $235.57 12,837 D
Explanation of Responses:
1. Distribution ratio for Phantom Stock Units is 1:1.
2. Phantom Stock Units are payable in cash only commencing at retirement.
By: Trevor L. Kingston, Attorney-in-Fact For: David B. Dillon 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Rhythm Pharmaceuticals (RYTM) shares did the CSO sell?

Alastair Garfield sold 1,319 common shares on 2-Jul-2025 at an average price of about $64.8 per share.

Was the insider sale pre-planned under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was executed under a Rule 10b5-1 plan adopted on 25-Jun-2024.

What was the purpose of the share sale disclosed in the Form 4?

The sale was solely to cover withholding taxes triggered by the RSU vesting event.

How many Rhythm Pharmaceuticals shares and RSUs does the CSO still hold?

Post-transaction, Garfield owns 3,126 common shares directly and 13,333 unvested RSUs.

When will the remaining RSUs vest?

The RSUs vest in 25 % annual installments on each anniversary of 1-Jul-2024 through 2028, subject to continued service.
Union Pacific

NYSE:UNP

UNP Rankings

UNP Latest News

UNP Latest SEC Filings

UNP Stock Data

133.60B
592.07M
0.23%
82.4%
1.27%
Railroads
Railroads, Line-haul Operating
United States
OMAHA